Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PETS's Cash to Debt is ranked higher than
96% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. PETS: No Debt )
PETS' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.84
PETS's Equity to Asset is ranked higher than
98% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. PETS: 0.84 )
PETS' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.95
Current: 0.84

-0.13
0.95
Interest Coverage No Debt
PETS's Interest Coverage is ranked higher than
91% of the 380 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.78 vs. PETS: No Debt )
PETS' s 10-Year Interest Coverage Range
Min: 15.27   Max: 9999.99
Current: No Debt

15.27
9999.99
F-Score: 6
Z-Score: 17.84
M-Score: -1.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.32
PETS's Operating margin (%) is ranked higher than
97% of the 522 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.55 vs. PETS: 12.32 )
PETS' s 10-Year Operating margin (%) Range
Min: -26.37   Max: 17.02
Current: 12.32

-26.37
17.02
Net-margin (%) 7.85
PETS's Net-margin (%) is ranked higher than
96% of the 522 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. PETS: 7.85 )
PETS' s 10-Year Net-margin (%) Range
Min: -28.25   Max: 10.91
Current: 7.85

-28.25
10.91
ROE (%) 26.41
PETS's ROE (%) is ranked higher than
95% of the 512 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.04 vs. PETS: 26.41 )
PETS' s 10-Year ROE (%) Range
Min: -236.77   Max: 90.8
Current: 26.41

-236.77
90.8
ROA (%) 22.81
PETS's ROA (%) is ranked higher than
99% of the 522 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.13 vs. PETS: 22.81 )
PETS' s 10-Year ROA (%) Range
Min: -52.2   Max: 47.63
Current: 22.81

-52.2
47.63
ROC (Joel Greenblatt) (%) 126.92
PETS's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 521 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.59 vs. PETS: 126.92 )
PETS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -165.66   Max: 194.27
Current: 126.92

-165.66
194.27
Revenue Growth (%) 4.40
PETS's Revenue Growth (%) is ranked higher than
74% of the 458 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. PETS: 4.40 )
PETS' s 10-Year Revenue Growth (%) Range
Min: 2.7   Max: 57.8
Current: 4.4

2.7
57.8
EBITDA Growth (%) -1.60
PETS's EBITDA Growth (%) is ranked higher than
67% of the 419 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. PETS: -1.60 )
PETS' s 10-Year EBITDA Growth (%) Range
Min: -8.7   Max: 109.3
Current: -1.6

-8.7
109.3
EPS Growth (%) -0.70
PETS's EPS Growth (%) is ranked higher than
70% of the 399 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.30 vs. PETS: -0.70 )
PETS' s 10-Year EPS Growth (%) Range
Min: -9   Max: 104.1
Current: -0.7

-9
104.1
» PETS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PETS Guru Trades in Q3 2013

Jim Simons 1,630,915 sh (+20.44%)
John Buckingham 119,189 sh (+0.53%)
Chuck Royce 56,000 sh (unchged)
John Hussman 15,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 19,800 sh (-32.65%)
» More
Q4 2013

PETS Guru Trades in Q4 2013

Chuck Royce 141,000 sh (+151.79%)
John Hussman 20,000 sh (+33.33%)
Jim Simons 1,893,015 sh (+16.07%)
John Buckingham 121,889 sh (+2.27%)
Paul Tudor Jones Sold Out
» More
Q1 2014

PETS Guru Trades in Q1 2014

John Burbank 13,364 sh (New)
Paul Tudor Jones 33,500 sh (New)
Chuck Royce 351,500 sh (+149.29%)
John Hussman 26,000 sh (+30%)
John Buckingham 130,106 sh (+6.74%)
Jim Simons 1,817,208 sh (-4%)
» More
Q2 2014

PETS Guru Trades in Q2 2014

John Buckingham 132,974 sh (+2.2%)
Chuck Royce 351,500 sh (unchged)
John Hussman Sold Out
Paul Tudor Jones Sold Out
John Burbank Sold Out
Jim Simons 1,695,407 sh (-6.7%)
» More
» Details

Insider Trades

Latest Guru Trades with PETS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Sold Out 0.03%$12.63 - $13.8 $ 13.684%0
John Burbank 2014-06-30 Sold Out $12.63 - $13.8 $ 13.684%0
John Hussman 2014-03-31 Add 30%0.01%$12.62 - $16.65 $ 13.68-2%26000
John Burbank 2014-03-31 New Buy$12.62 - $16.65 $ 13.68-2%13364
John Hussman 2013-12-31 Add 33.33%0.01%$14.58 - $16.86 $ 13.68-12%20000
Joel Greenblatt 2013-09-30 Sold Out 0.02%$12.82 - $17.17 $ 13.68-12%0
Joel Greenblatt 2013-06-30 Reduce -78.51%0.08%$12.37 - $13.73 $ 13.685%32909
John Hussman 2013-06-30 New Buy0.01%$12.37 - $13.73 $ 13.685%15000
Joel Greenblatt 2013-03-31 Add 39.37%0.03%$11.09 - $14.37 $ 13.687%153161
Joel Greenblatt 2012-06-30 Add 162.75%0.06%$11.15 - $13.46 $ 13.6812%102679
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.90
PETS's P/E(ttm) is ranked higher than
85% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.10 vs. PETS: 14.90 )
PETS' s 10-Year P/E(ttm) Range
Min: 11.25   Max: 50.06
Current: 14.9

11.25
50.06
P/B 3.83
PETS's P/B is ranked higher than
57% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.05 vs. PETS: 3.83 )
PETS' s 10-Year P/B Range
Min: 2.33   Max: 20.8
Current: 3.83

2.33
20.8
P/S 1.18
PETS's P/S is ranked higher than
55% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. PETS: 1.18 )
PETS' s 10-Year P/S Range
Min: 0.84   Max: 3.51
Current: 1.18

0.84
3.51
PFCF 35.08
PETS's PFCF is ranked higher than
82% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 184.57 vs. PETS: 35.08 )
PETS' s 10-Year PFCF Range
Min: 7.86   Max: 1221.5
Current: 35.08

7.86
1221.5
EV-to-EBIT 8.19
PETS's EV-to-EBIT is ranked higher than
92% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.69 vs. PETS: 8.19 )
PETS' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 36.1
Current: 8.19

4.7
36.1
Shiller P/E 13.78
PETS's Shiller P/E is ranked higher than
94% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 34.28 vs. PETS: 13.78 )
PETS' s 10-Year Shiller P/E Range
Min: 9.84   Max: 124.94
Current: 13.78

9.84
124.94
Current Ratio 5.89
PETS's Current Ratio is ranked higher than
99% of the 518 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.17 vs. PETS: 5.89 )
PETS' s 10-Year Current Ratio Range
Min: 0.29   Max: 17.46
Current: 5.89

0.29
17.46
Quick Ratio 3.52
PETS's Quick Ratio is ranked higher than
98% of the 518 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.68 vs. PETS: 3.52 )
PETS' s 10-Year Quick Ratio Range
Min: 0.11   Max: 14.61
Current: 3.52

0.11
14.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.90
PETS's Dividend Yield is ranked higher than
92% of the 447 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.81 vs. PETS: 4.90 )
PETS' s 10-Year Dividend Yield Range
Min: 0.51   Max: 5.85
Current: 4.9

0.51
5.85
Dividend Payout 0.75
PETS's Dividend Payout is ranked higher than
60% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. PETS: 0.75 )
PETS' s 10-Year Dividend Payout Range
Min: 0.31   Max: 0.81
Current: 0.75

0.31
0.81
Dividend growth (3y) 11.60
PETS's Dividend growth (3y) is ranked higher than
87% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.40 vs. PETS: 11.60 )
PETS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 26
Current: 11.6

0
26
Yield on cost (5-Year) 12.14
PETS's Yield on cost (5-Year) is ranked higher than
97% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.02 vs. PETS: 12.14 )
PETS' s 10-Year Yield on cost (5-Year) Range
Min: 1.26   Max: 14.5
Current: 12.14

1.26
14.5
Share Buyback Rate 4.00
PETS's Share Buyback Rate is ranked higher than
93% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. PETS: 4.00 )
PETS' s 10-Year Share Buyback Rate Range
Min: 4.1   Max: -48.2
Current: 4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.94
PETS's Price/Net Cash is ranked higher than
98% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. PETS: 8.94 )
PETS' s 10-Year Price/Net Cash Range
Min: 3.77   Max: 34.59
Current: 8.94

3.77
34.59
Price/Net Current Asset Value 5.70
PETS's Price/Net Current Asset Value is ranked higher than
97% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. PETS: 5.70 )
PETS' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 236
Current: 5.7

3.12
236
Price/Tangible Book 3.88
PETS's Price/Tangible Book is ranked higher than
66% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.42 vs. PETS: 3.88 )
PETS' s 10-Year Price/Tangible Book Range
Min: 1.56   Max: 36.5
Current: 3.88

1.56
36.5
Price/DCF (Projected) 1.10
PETS's Price/DCF (Projected) is ranked higher than
89% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.48 vs. PETS: 1.10 )
PETS' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 6.04
Current: 1.1

0.54
6.04
Price/Median PS Value 0.73
PETS's Price/Median PS Value is ranked higher than
91% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.12 vs. PETS: 0.73 )
PETS' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 1.93
Current: 0.73

0.14
1.93
Price/Graham Number 1.62
PETS's Price/Graham Number is ranked higher than
78% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.29 vs. PETS: 1.62 )
PETS' s 10-Year Price/Graham Number Range
Min: 1.06   Max: 5.73
Current: 1.62

1.06
5.73
Earnings Yield (Greenblatt) 12.20
PETS's Earnings Yield (Greenblatt) is ranked higher than
90% of the 500 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.80 vs. PETS: 12.20 )
PETS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.8   Max: 21.2
Current: 12.2

2.8
21.2
Forward Rate of Return (Yacktman) 1.07
PETS's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 386 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.65 vs. PETS: 1.07 )
PETS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 64.7
Current: 1.07

0.1
64.7

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, GNC, APNHY, JCOUF, PMC » details
Traded in other countries:PQM.Germany
PetMed Express, Inc. was incorporated in the state of Florida in January 1996. The company is a nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. The Company offers consumers an alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. Its current product line contains approximately 3000 SKUS. These products include a majority of the well-known brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx, and Rimadyl. In March 2010, the Company started offering for sale additional pet supplies on its website, which are drop shipped to its customers with third parties. These pet supplies include: food, beds, crates, stairs, strollers, and other popular pet supplies. It attracted approximately 22.7 million visitors to its website during fiscal 2013. Its website allows customers to easily browse and purchase all of its products online. Its website is designed to be fast, secure, and easy to use with order and shipping confirmations, and with online order tracking capabilities. It provides its customers with toll-free telephone access to its customer care representatives. Its call center generally operates from 8:00 AM to 11:00 PM, Monday through Thursday, 8:00 AM to 9:00 PM on Friday, 9:00 AM to 6:00 PM on Saturday, and 10:00 AM to 5:00 PM on Sunday, Eastern Time. The process of customers purchasing products from 1-800-PetMeds consists of a few simple steps. A customer first places a call to its toll-free telephone number or visits its website. The following information is needed to process prescription orders: pet information, prescription information, and the veterinarian's name and phone number. This information is entered into its computer system. Then its pharmacists and pharmacy technicians verify all prescriptions. The order process system checks for the verification for prescription medication orders and a valid payment method for all orders. An invoice is generated and printed in its fulfillment center, where items are picked, and then shipped via United States Postal Service, Federal Express, or UPS. Its customers enjoy the convenience of rapid home delivery, with approximately 80% of all orders being shipped within 24 hours of ordering. Its operations are subject to regulation by the State of Florida and are licensed as a community pharmacy by the Florida Board of Pharmacy.
» More Articles for PETS

Headlines

Articles On GuruFocus.com
Bob Olstein Says Forget Amazon, Buy PetSmart, Teradata Jun 13 2014 
PetMed Express Inc. Is Trying Harder to Push Sales Apr 21 2014 
4 Cash Gushing, Undervalued Small Cap Stocks With Zero Debt Apr 08 2014 
4 Biggest Dividend Challengers with Low Debt and Nice Initial Yields Aug 28 2013 
12 Dividend Stocks Sending More Cash to Shareholders Aug 05 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
comment on PETS Mar 02 2013 
comment on PETS Mar 02 2013 
PetMed Express - Debt-Free with Attractive Dividend Yield Nov 26 2012 
comment on PETS Nov 13 2012 


More From Other Websites
Stock Futures Point Lower; Recalls Trip Up Hertz Global Aug 20 2014
PETMED EXPRESS INC Financials Aug 02 2014
PETMED EXPRESS INC Files SEC form 10-Q, Quarterly Report Jul 29 2014
PETMED EXPRESS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 28 2014
PETMED EXPRESS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 23 2014
PetMed Posts In Line Q1 Earnings, Revenues on Lower Orders Jul 22 2014
PETMED EXPRESS INC Files SEC form 8-K, Other Events Jul 21 2014
[$$] PetMed Express Profit Rises 4.6% Jul 21 2014
PetMed Express D/B/A 1-800-PetMeds Announces Its First Quarter Financial Results and Its $0.17 Per... Jul 21 2014
Q1 2014 Petmed Express Inc Earnings Release - 08:00 am ET Jul 21 2014
PETMED EXPRESS INC Files SEC form 8-K, Other Events Jul 18 2014
Can Advanced Micro (AMD) Surprise This Earnings Season? Jul 15 2014
PetMed Express D/B/A 1-800-PetMeds to Announce Its First Quarter Financial Results on July 21, 2014 Jul 14 2014
Must-know: An overview of PetSmart’s growth drivers Jul 10 2014
Why A Short Covering Rally Might Come for Petmed Express (PETS) Stock Jul 10 2014
Must-know: An overview of PetSmart’s businesses Jul 09 2014
PetMed Raised to Buy on Solid Growth Strategies Jul 01 2014
PetMed Down to Sell Jun 09 2014
PETMED EXPRESS INC Files SEC form 10-K, Annual Report May 27 2014
PetMed Express: Updated Research Report May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK